Claris Bio Raises $118M for a Drug Alternative to Corneal Surgery

Claris Bio has raised enough capital to move its lead eye-disease treatment toward the studies that could determine whether it reaches patients.

What happened

The biotechnology company closed a $118 million Series B to advance CSB-001, an ophthalmic treatment for limbal stem cell deficiency.

Claris plans to begin pivotal studies in the first half of 2027. The company says there is currently no drug approved specifically for the condition, which damages the cells responsible for maintaining and repairing the cornea.

Why it matters

Severe cases can require complex surgical treatment. A successful drug could provide a less invasive option and potentially reach patients who are not well served by existing approaches.

The round may finance both late-stage clinical development and preparations for commercialisation. That reduces the need for Claris to return immediately to investors while approaching expensive pivotal trials.

The bigger picture

The deal shows that investors still support late-stage biotechnology when a company targets a clear unmet medical need and has a defined route to regulatory testing.

But the risk remains substantial. Early results do not guarantee success in larger trials, and the treatment’s efficacy claims are still based on company-reported clinical data. The pivotal programme will be the real test of whether CSB-001 can become a practical alternative to surgery.